Form 4: Altimmune Director Philip Hodges Receives Stock Options

Director Philip Hodges was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Summary

• Director Philip Hodges received a grant of 48,800 stock options on May 1, 2026.
• The options have an exercise price of $2.82 per share.
• The options are set to expire on May 1, 2036.
• Vesting occurs in substantially equal monthly installments over a 12-month period following the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Altimmune common stock.
• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest over the 12 months following May 1, 2026, provided the director remains in service.

Management Comments

• The options were granted pursuant to the Company's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of 12-month vesting schedules for director equity is consistent with standard practices for small-cap biotech firms.
• The grant size is typical for non-employee director annual compensation packages in the pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options in monthly installments through May 2027.

Key Dates

Keywords

Altimmune, ALT, Form 4, Insider Trading, Stock Options, Director Compensation